Page 95 - Ram Prasad Sahu/undefined

Growth hurdles for Mahindra & Mahindra

Increasing competition, higher product prices post Budget and running costs could moderate growth rates, going ahead

Strides Arcolab falls on cash utilisation uncertainty

The Indian company is expected to get a further $250 million if it is able to meet certain conditions

Why Etihad deal is a big positive for Jet

Experts say that three pairs of Heathrow Airport parking slots sale & the deal when it comes through will be a positive for Jet Airways

Prefer Hero to Bajaj on valuations: Analysts

Fortune Research is upgrading rating, target price (Rs 1,962, CMP: 1,690) as valuations have hit a two year low

Higher competition, falling demand could squeeze margins of Apollo tyres

The company's stock jumped 3% on Friday after CLSA Mauritius hiked its stake in the company to 5%

Consistent show key for Thomas Cook's re-rating

Pricing policy overhang to limit upside for GSK Pharma

Ability to maintain sales growth and hold on to margins are other critical areas to watch

Pharma sector: Maintaining growth on a high base

Buoyed by revenue growth and favourable currency, the margins are likely to improve on a y-o-y basis

Will course correction help Fortis Healthcare?

Firm wants to cut debt, go slow on mergers and acquisitions. But margins could take a hit

Maruti, M&M stand out in a poor quarter

Muted volumes across sectors, with an exception in utility and light commercial vehicles, spoil show for the auto sector

Strong US portfolio to help Lupin sustain growth

While increasing competition for a key product is a negative, the company¿s broad US portfolio as well as new launches will help offset any potential revenue loss

Strong US portfolio to help Lupin sustain growth

While increasing competition for a key product is a negative, the company's broad US portfolio as well as new launches will help offset any potential revenue loss

Hero MotoCorp: Costs dent performance

While volumes have recovered, operating profit margins fall steeply due to rise in raw material & sales promotion costs

Analysis: Fortis HealthCare moving in the right direction

The deal to sell its Australian assets will help pare debt, while its focus on Asian business especially India coupled with an asset light model will help drive growth

Fortis Healthcare moving in the right direction

Deal to sell its Australian assets will help pare debt, while focus on Asian business, especially India, will help drive growth

Multiple triggers in Glenmark

The strong outlook for the company is due to a robust US product pipeline, faster-than-industry growth in India as well as potential research upsides

DLF: Cut in debt on track, eyes new launches

If it manages to dispose of windmill assets, expected to generate Rs 900 cr, it would be able to bring down net debt to Rs 18,500 cr

DLF's debt reduction on track, eye on new launches

Deal closure, other asset sales over the next couple of months will help the company raise about Rs 4,750 cr from divestments in line with guidance

Multiple triggers in Glenmark Pharma

The strong outlook for the company is due to a robust US product pipeline, faster than industry growth in India as well as potential research upsides

Encore for pharmaceuticals, FMCG outlook cautious

While analysts believe FMCG sector valuations are high, pharmaceutical stocks are likely to put up a strong show in 2013